ABSTRACT
ABSTRACT Total PSA, although imperfect, remains the rst line test for prostate cancer screening: the sequential use of complementary tests may improve the diagnostic accuracy, not only in detecting prostate cancer but also in detecting signicant tumors that are likely to cause illness during the patient’s life. In modern health economics, the cost of new tests is important, especially in the public health system, and thus is a parameter that needs to be considered. Prostate biopsy is not a test without side effects, and thus, biomarkers that reduce the necessity of prostate biopsies are necessary.
